Inhibition of the MUC1-C oncoprotein induces multiple myeloma cell death by down-regulating TIGAR expression and depleting NADPH

Blood

Volumn 119, Issue 3, 2012, Pages 810-816

  Yin, Li ^a   Kosugi, Michio ^a   Kufe, Donald ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CARDIOLIPIN; GLUTATHIONE; GO 203; MUC1 C ONCOPROTEIN; MUCIN 1; ONCOPROTEIN; PROTEIN P53; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; TP53 INDUCED GLYCOLYSIS AND APOPTOSIS REGULATOR PROTEIN; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CELL DEATH; DOWN REGULATION; GLYCOLYSIS; HUMAN; HUMAN CELL; MEMBRANE POTENTIAL; MULTIPLE MYELOMA; OXIDATION; PRIORITY JOURNAL; PROTEIN EXPRESSION;

EID: 84856072436     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-07-369686     Document Type: Article

References (38)

1. Palumbo A, Anderson K. Multiple myeloma. N Engl J Med. 2011;364(11):1046-1060.
2. Takahashi T, Makiguchi Y, Hinoda Y, et al. Expression of MUC-1 on myeloma cells and induction of HLA-unrestricted CTL against MUC1 from a multiple myeloma patient. J Immunol. 1994;153: 2102-2109. (Pubitemid 24256681)
3. Burton J, Mishina D, Cardillo T, et al. Epithelial mucin-1 (MUC1) expression and MA5 anti-MUC1 monoclonal antibody targeting in multiple myeloma. Clin Cancer Res. 1999;5(10 suppl):3065- 3072.
4. Treon SP, Mollick JA, Urashima M, et al. Muc-1 core protein is expressed on multiple myeloma cells and is induced by dexamethasone. Blood. 1999;93:1287-1298. (Pubitemid 29076144)
5. Paydas S, Sahin B, Gonlusen G, Hazar B, Zorludemir S. MUC1 expression in plasmacytoma. Leuk Res. 2001;25(3):221-225. (Pubitemid 32157019)
6. Cloosen S, Gratama J, van Leeuwen EB, et al. Cancer specific Mucin-1 glycoforms are expressed on multiple myeloma. Br J Haematol. 2006;135(4):513-516. (Pubitemid 44583416)
7. Baldus SE, Palmen C, Thiele J. MUC1 (EMA) expressing plasma cells in bone marrow infiltrated by plasma cell myeloma. Histol Histopathol. 2007;22(8):889-893. (Pubitemid 47034155)
8. Kawano T,Ahmad R, Nogi H, Agata N, Anderson K, Kufe D. MUC1 oncoprotein promotes growth and survival of human multiple myeloma cells Int J Oncol. 2008;33:153-159.
9. Kufe D. Mucins in cancer: function, prognosis and therapy. Nature Reviews Cancer. 2009;9(12): 874-885.
10. Ramasamy S, Duraisamy S, Barbashov S, Kawano T, Kharbanda S, Kufe D. The MUC1 and galectin-3 oncoproteins function in a microRNA-dependent regulatory loop. Mol Cell. 2007;27(6): 992-1004. (Pubitemid 47488189)
11. Li Y, Liu D, Chen D, Kharbanda S, Kufe D. Human DF3/MUC1 carcinoma-associated protein functions as an oncogene. Oncogene. 2003;22: 6107-6110. (Pubitemid 37175889)
12. Huang L, Chen D, Liu D, Yin L, Kharbanda S, Kufe D. MUC1 oncoprotein blocks GSK3beta-mediated phosphorylation and degradation of beta-catenin. Cancer Res. 2005;65(22):10413- 10422.
13. Li Y, Chen W, Ren J, et al. DF3/MUC1 signaling in multiple myeloma cells is regulated by interleukin- 7. Cancer Biol Ther. 2003;2:187-193.
14. Leng Y, Cao C, Ren J, et al. Nuclear import of the MUC1-C oncoprotein is mediated by nucleoporin Nup62. J Biol Chem. 2007;282(27):19321-19330. (Pubitemid 47100108)
15. Raina D, Ahmad R, Joshi M, et al. Direct targeting of the MUC1 oncoprotein blocks survival and tumorigenicity of human breast carcinoma cells. Cancer Res. 2009;69(12):5133-5141.
16. Yin L, Ahmad R, Kosugi M, et al. Survival of human multiple myeloma cells is dependent on MUC1 C-terminal transmembrane subunit onco-protein function. Mol Pharm. 2010;78:166-174.
17. Yin L, Kufe D. Human MUC1 carcinoma antigen regulates intracellular oxidant levels and the apoptotic response to oxidative stress. J Biol Chem. 2003;278(37):35458-35464. (Pubitemid 37102316)
18. Yin L, Huang L, Kufe D. MUC1 oncoprotein activates the FOXO3a transcription factor in a survival response to oxidative stress. J Biol Chem. 2004;279(44):45721-45727. (Pubitemid 39491562)
19. Yin L, Kharbanda S, Kufe D. Mucin 1 oncoprotein blocks hypoxia-inducible factor 1 alpha activation in a survival response to hypoxia. J Biol Chem. 2007;282(1):257-266. (Pubitemid 47076647)
20. Yin L, Kharbanda S, Kufe D. MUC1 oncoprotein promotes autophagy in a survival response to glucose deprivation. Int J Oncol. 2009;34(6): 1691-1699.
21. Pei XY, Dai Y, Grant S. Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors. Clin Cancer Res. 2004;10(11):3839-3852. (Pubitemid 38697620)
22. Feng R, Oton A, Mapara MY, Anderson G, Belani C, Lentzsch S. The histone deacetylase inhibitor, PXD101, potentiates bortezomib-induced anti-multiple myeloma effect by induction of oxidative stress and DNAdamage. Br J Haematol. 2007;139(3):385- 397.
23. Nair RR, Emmons MF, Cress AE, et al. HYD1- induced increase in reactive oxygen species leads to autophagy and necrotic cell death in multiple myeloma cells. Mol Cancer Ther. 2009;8(8): 2441-2451.
24. Bensaad K, Tsuruta A, Selak MA, et al. TIGAR, a p53-inducible regulator of glycolysis and apoptosis. Cell. 2006;126(1):107-120. (Pubitemid 44040989)
25. Karawajew L, Rhein P, Czerwony G, Ludwig WD. Stress-induced activation of the p53 tumor suppressor in leukemia cells and normal lymphocytes requires mitochondrial activity and reactive oxygen species. Blood. 2005;105(12):4767- 4775. (Pubitemid 40807302)
26. Furugaki K, Iwai T, Shirane M, Kondoh K, Moriya Y, Mori K. Schedule-dependent antitumor activity of the combination with erlotinib and docetaxel in human non-small cell lung cancer cells with EGFR mutation, KRAS mutation or both wild-type EGFR and KRAS. Oncology Reports. 2010;24(5):1141- 1146.
27. Liu Q, Hilsenbeck S, Gazitt Y. Arsenic trioxide-induced apoptosis in myeloma cells: p53-dependent G1 or G2/M cell cycle arrest, activation of caspase-8 or caspase-9, and synergy with APO2/ TRAIL. Blood. 2003;101(10):4078-4087. (Pubitemid 36857889)
28. Otsuki T, Yata K, Sakaguchi H, et al. Interleukin 10 abolishes the growth inhibitory effects of all-trans retinoic acid on human myeloma cells. Br J Haematol. 2002;116(4):787-795. (Pubitemid 34226997)
29. Pichiorri F, Suh SS, Rocci A, et al. Downregulation of p53-inducible microRNAs 192, 194, and 215 impairs the p53/MDM2 autoregulatory loop in multiple myeloma development. Cancer Cell. 2010;18(4):367-381.
30. Brookes PS, Levonen AL, Shiva S, Sarti P, Darley-Usmar VM. Mitochondria: regulators of signal transduction by reactive oxygen and nitrogen species. Free Radic Biol Med. 2002;33(6): 755-764. (Pubitemid 35232311)
31. Lui VW, Wong EY, Ho K, et al. Inhibition of c-Met downregulates TIGAR expression and reduces NADPH production leading to cell death. Oncogene. 2011;30(9):1127-1134.
32. Ren J, Agata N, Chen D, et al. Human MUC1 carcinoma-associated protein confers resistance to genotoxic anti-cancer agents. Cancer Cell. 2004;5(2):163-175. (Pubitemid 38283802)
33. Ren J, Raina D, Chen W, Li G, Huang L, Kufe D. MUC1 oncoprotein functions in activation of fibroblast growth factor receptor signaling. Mol Cancer Res. 2006;4(11):873-883. (Pubitemid 44877017)
34. Ren J, Bharti A, Raina D, Chen W, Ahmad R, Kufe D. MUC1 oncoprotein is targeted to mitochondria by heregulin-induced activation of c-Src and the molecular chaperone HSP90. Oncogene. 2006;25(1):20-31. (Pubitemid 43050000)
35. Tian WN, Braunstein LD, Apse K, et al. Importance of glucose-6-phosphate dehydrogenase activity in cell death. Am J Physiol. 1999;276(5 pt 1):C1121-C1131. (Pubitemid 29244667)
36. Fico A, Paglialunga F, Cigliano L, et al. Glucose- 6-phosphate dehydrogenase plays a crucial role in protection from redox-stress-induced apoptosis. Cell Death Differ. 2004;11(8):823-831. (Pubitemid 39139742)
37. Joshi MD, Ahmad R, Raina D, et al. MUC1 oncoprotein is a druggable target in human prostate cancer cells. Mol Cancer Ther. 2009;8(11):3056- 3065.
38. Yin L, Wu Z, Avigan D, et al. MUC1-C oncoprotein suppresses reactive oxygen species-induced terminal differentiation of acute myelogenous leukemia cells Blood. 2011;117(18):4863-4870.